CA2958040C - Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives - Google Patents
Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives Download PDFInfo
- Publication number
- CA2958040C CA2958040C CA2958040A CA2958040A CA2958040C CA 2958040 C CA2958040 C CA 2958040C CA 2958040 A CA2958040 A CA 2958040A CA 2958040 A CA2958040 A CA 2958040A CA 2958040 C CA2958040 C CA 2958040C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- process according
- acid
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 | ||
| NLPCT/NL2014/050556 | 2014-08-12 | ||
| PCT/NL2015/050555 WO2016024858A1 (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2958040A1 CA2958040A1 (en) | 2016-02-18 |
| CA2958040C true CA2958040C (en) | 2022-09-13 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2958040A Active CA2958040C (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (https=) |
| EP (2) | EP3180314B1 (https=) |
| JP (1) | JP6670310B2 (https=) |
| KR (1) | KR102572626B1 (https=) |
| CN (1) | CN107108558B (https=) |
| AR (1) | AR101509A1 (https=) |
| AU (1) | AU2015302407B2 (https=) |
| BR (1) | BR112017002873B1 (https=) |
| CA (1) | CA2958040C (https=) |
| CL (1) | CL2017000367A1 (https=) |
| CY (1) | CY1125574T1 (https=) |
| DK (1) | DK3180314T3 (https=) |
| EA (1) | EA034357B1 (https=) |
| ES (1) | ES2926775T3 (https=) |
| HR (1) | HRP20221061T1 (https=) |
| HU (1) | HUE059947T2 (https=) |
| IL (1) | IL250525B (https=) |
| LT (1) | LT3180314T (https=) |
| MA (1) | MA40378B1 (https=) |
| MX (1) | MX367908B (https=) |
| PL (1) | PL3180314T3 (https=) |
| PT (1) | PT3180314T (https=) |
| RS (1) | RS63575B1 (https=) |
| SG (1) | SG11201701077XA (https=) |
| SI (1) | SI3180314T1 (https=) |
| SM (1) | SMT202200385T1 (https=) |
| TW (1) | TWI691490B (https=) |
| WO (1) | WO2016024858A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4125911B1 (en) | 2021-03-05 | 2024-04-24 | NewAmsterdam Pharma B.V. | Obicetrapib for treatment of dementias |
| IL310115A (en) | 2021-07-26 | 2024-03-01 | Newamsterdam Pharma B V | Treatment of his hyporesponders |
| AU2022425078A1 (en) | 2021-12-30 | 2024-08-08 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| CU20250001A7 (es) | 2022-07-05 | 2025-10-17 | Newamsterdam Pharma B V | Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos |
| TW202416994A (zh) | 2022-08-22 | 2024-05-01 | 荷蘭商新阿姆斯特丹製藥公司 | 固定劑量醫藥組合物及其用途 |
| EP4661865A1 (en) | 2023-02-07 | 2025-12-17 | NewAmsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| WO2026062050A1 (en) | 2024-09-17 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
| WO2026062049A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V., | Obicetrapib for the treatment of dementias |
| WO2026063944A1 (en) | 2024-09-21 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for the treatment of dementias |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| ATE316957T1 (de) * | 2001-04-30 | 2006-02-15 | Pfizer Prod Inc | Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
| TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
-
2015
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en not_active Ceased
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
-
2022
- 2022-09-22 CY CY20221100631T patent/CY1125574T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2958040C (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| EP0498721B1 (fr) | Dérivés N-substitués de la quinoléine, leur procédé de préparation, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant | |
| RS56096B1 (sr) | Deuterisani derivati ivakaftora | |
| EP3215510B1 (en) | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | |
| EP2185561B1 (fr) | Dérivés de 1,2,3,4-tétrahydropyrrolo(1,2-a)pyrazine-6-carboxamides et de 2,3,4,5-tétrahydropyrrolo(1,2-a)-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
| US10357499B2 (en) | Substituted triazolobenzodiazepines | |
| HK40081593A (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| TW200829568A (en) | Quinolone derivative or pharmaceutically acceptable salt thereof | |
| EP2138490A1 (fr) | Nouveau procédé de synthèse de fluoroquinolones | |
| JP2006512378A (ja) | ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体 | |
| HK1239687A1 (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| HK1239687B (zh) | 制备用於制备四氢喹啉衍生物的合成中间体的方法 | |
| KR20000059756A (ko) | 피라졸로피리미디논 유도체와 이의 제조방법그리고 이의 용도 | |
| JP2003104988A (ja) | 抗菌剤として有用なキノロン誘導体 | |
| FR2672597A1 (fr) | Nouveaux derives n-substitues de la quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. | |
| JP2000191663A (ja) | 縮合ピリダジン誘導体の製造法 | |
| JPWO1996033169A1 (ja) | １−［ω−（３，４−ジヒドロ−２−ナフタレニル）アルキル］環状アミン誘導体、その製造方法及びそれを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200311 |